Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865163 | 0.88 | PDE4B (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7863692 | 0.88 | ROCK2 (0.37) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7865866 | 0.88 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10186853 | 0.85 | PDE4B (0.34) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7861154 | 0.84 | PDE4B (0.35) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10186839 | 0.83 | PDE4B (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7855587 | 0.83 | SOS1 (0.42) | PDE4APDE4BPDE4CPDE4DSOS1 | |
| SCHEMBL7855584 | 0.83 | PDE4B (0.33) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7862393 | 0.82 | PDE4B (0.43) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7865820 | 0.82 | ROCK2 (0.41) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | SLC6A4 4340/4885HTR2A 4122/4885KCNH2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.